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Summary
The p73 protein shares structural and functional similarities
with the tumour-suppressor p53, but its role in neoplastic
transformation is unknown. Alternative splicing leads to the
expression of at least nine p73 C-terminal mRNA splice
variants (a, (3, y, 5, e, £,, x\, r\ 1, 8). In this survey, we analyse the
expression of p73 by real-time quantitative RT-PCR, its
known C-terminal variants with an RT-PCR-Southern tech-
nique and by Western blot in samples of 51 patients with
B-CLL, normal B lymphocytes from eight individuals, and
five haematopoetic cell lines. p73a protein expression posi-
tively correlated with higher risk B-CLL stages (P = 0.046).
Total p73 mRNA expression was higher (P = 0.01) and p73ot
protein more frequently detected (P = 0.008) in B-CLL com-
pared with normal CD19+-B-lymphocytes. p73 C-terminal
mRNA variants were expressed both in B-CLL and in normal
B-lymphocytes, but their expression was biased since the y
{P - 0.041), the 0 (P < 0.001), and the r\ variant (P - 0.033)
prevailed in normal B-lymphocytes. In summary, we con-
clude that the accumulation of p73, the expression pattern of
particular p73 variants and its link to progression may play a
distinct role in the molecular pathology B-CLL.
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Introduction
B-cell chronic lymphocytic leukaemia (B-CLL), the
most frequent adult leukaemia in Western countries,
results from slow clonal accumulation of neoplastic,
and mature appearing B lymphocytes. Most cells are in
the G0/G1 phase of the cell cycle and therefore do not
proliferate [1]. B-CLL is a heterogeneous disease, mainly
characterized by failed programmed cell death [2]. So
far, only few genes involved in its molecular pathology
have been identified [3]. In B-CLL, p53-inactivating
mutations are associated with an excess of prolympho-
cytes, poor response to treatment with purine ana-
logues, and poor survival. Such mutations have been
reported for a small percentage of B-CLL patients only
p73 is a gene with structural and functional similar-
ities to p53 [5]. At least nine different p73 C-terminal
mRNA splice variants (a, p, y, 5, e, £,, r\, r\\, 9) are
known. The variants P to 9 result in truncated forms of
the C-terminal full length p73oc protein; variants P, y, 5,
E, r\\, and 0 use an alternative reading frame leading to
the formation of different C-termini compared with
p73oc [6-8]. The p73 C-terminal mRNA splice variants
differ in vitro in their potential to activate p53-respon-
sive genes such as p21Wafl/ciP' and BAX [6]. The struc-
tural homology of p73 with p53 as well as its local-
ization on chromosome Ip36.1, a region frequently
deleted in various tumours [5] initially suggested that
p73 might also act as a tumour suppressor. Indeed,
overexpression of p73 in vitro can induce irreversible
cell cycle and growth arrest [5, 6, 9], and promote
apoptosis, even in the absence of p53 [10]. Despite these
similarities, several lines of evidence suggest a func-
tional difference between p73 and p53. The genes differ
in their interaction with viral oncoproteins [11]. Mdm2
inhibits p73, but in contrast to p53 without degradation
[12]. DNA damage induces p73, albeit through a dis-
tinct, p53-independent pathway [11]. In contrast to p53,
mutations of the p73 gene are very rare in human
cancers including haematological malignancies [11, 13-
15], and p73-knockout-mice do not develop spontane-
ous tumours [16]. Finally, p73 mRNA expression is
increased rather than absent in a variety of tumours
relative to their homologous normal tissues [11]. The
overexpression of the p73 gene may be a mechanism of
p53-inactivation in p53 wild-type tumours through
competition for DNA binding sites [17]. Although the
role of p73 in tumorigenesis is unknown, it was shown
that the high expression of p73 is positively correlated
with poor prognosis in hepatocellular carcinoma [18]
and with progression of bladder tumours [19]. Data
on p73 expression in B-CLL have not yet been pub-
lished. We have therefore studied the expression of p73




Patient samples, normal controls, and cell lines
Peripheral blood samples from 51 patients with typical B-CLL accord-
ing to standard clinical and laboratory findings [20] including a
minimal Matutes-Score of four [21] were prospectively collected with
informed consent. The mean age was 65 years (range 38-85) and the
" male_to female ratio was 1.83:1. B-CLL were classified according to
the modified Rai-stage [22], and patients with autoimmune anaemia
and/or thrombocytopenia were classified separately as high risk/im-
mune cases [23]. Twelve of fifty-one (23.5%) patients were in the high
risk, 6 of 51 (11.8%) in the high risk/immune, 27 of 51 (52.9%) in the
intermediate risk, and 6 of 51 (11.8%) in the low risk group. At the time
of sampling. 18 of 51 patients (35.3%) had never been treated. 25 of 51
patients (49%) had received treatment > two months prior to sample
collection, and 8 of 51 patients (15%) were under treatment with
different regimens. Malignant B-lymphocytes were isolated by density
gradient centrifugation on Lymphoprep (Nycomed Pharma AS: Oslo.
Norway). A purity of >90% mononuclear cells was obtained as
assessed microscopically. Normal CD19+-B-lymphocytes were iso-
lated from peripheral blood (Figure 2. nos. 1-3, 5). normal spleens
(nos. 4,6 and 7) and tonsils (no 8) (spleen and tonsil samples were kind
gifts from S. Miescher, Berne, Switzerland). Positive selection was
performed using magnetic beads coated with anti-CDI9 antibodies
according to the manufacturer's protocol (Dynal A.S. Oslo. Norway)
with a purity of >90% measured by flow cytometry Three lymphoid
(JVM-2 (B-CLL). RPMI-8402 (T-ALL). the Jurkat (T-cell leukaemia)
and two myeloid leukaemic cell lines (Kasumi-1 (AML). K562 (CML
in blast crisis) were obtained from the German Collection of Micro-
organisms and Cell Cultures (DSMZ: Braunschweig, Germany) and
were grown in RPMI-1640 (Sigma: St. Louis. Missouri) with 10% FCS.
RNA extraction, RT-PCR and real-time quantitative PCR
Total RNA was extracted using the RNeasy Mini Kit® (Qiagen. Basel.
Switzerland). Synthesis of first strand cDNA and the real-time quanti-
tative RT-PCR were performed as previously described [24. 25],
Briefly, total p73 was amplified by PCR using primers in exons 5 and
6 of p73. The TaqMan probe hybridized to a sequence of exon 6. The
(5-actin gene was used for normalization. All measurements were
performed twice, and the arithmetic mean was used for further calcu-
lations.
Determination of C-terminal p73 mRNA splice variants
C-tcrminal mRNA splice variants of p73 were detected as previously
described [24, 26]. Briefly, all known p73 C-terminal mRNA splice
variants were amplified using a forward primer in exon 8 and a reverse
primer in exon 14. The PCR products were Southern blotted, hybri-
dized to a PCR generated, digoxigenin labeled probe and identified by
length. As a control, the human glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was amplified in parallel
Protein analysis
The protein extraction was performed as described [24]. 120 ug total
cellular protein was Western blotted, and a polyclonal antibody against
p73 (a kind gift from D Caput, Labege, France [5]) was used [24, 25].
Equal loading and transfer were assessed by Ponceau staining The cell
line K562 was used as a positive, and Kasumi-1 as a negative control
[24, 25]. The p73 isoforms a and p were synthesized in vitro by TNT
T7 Quick Coupled Transcription/Translation System according to the
manufacturer's protocol (Promega.Wallisellen. Switzerland) from p73a-
and (5-HA-pcDNA3 plasmids (kind gifts from V. Delaurenzi. Rome.
Italy [6]), and were used as standards for the Western blots. To assess
for protein quality of the patient samples, 50 ug of protein was Western
blotted and detected with a rabbit polyclonal antibody against actin
(A2066. Sigma, Buchs, Switzerland).
Statistical analysis
The expression of p73 was compared by Mests and analysis of variance
of the log-transformed ratios of p73 and P-actin. The data were tested
for normality by constructing Q-Q-plots and with the Komolgorov-
Smirnov procedure, and for equal variances with the Levene test.
Tukey's least significant difference was used for the post-hoc compar-
ison of individual risk groups Categorical data were analysed in
contingency tables and tested for significant differences by x2 and by
Fisher's exact test as appropriate. Spearmen's rank correlation was
used for correlation coefficients. All high risk/immune cases were
excluded from the correlation analysis since this group can not be
ordered appropriately according to the modified Rai staging system
[23, 27]. SPSS for Windows 8.0 was used for the calculations.
Results
Totalp73 mRNA expression is significantly increased in
B-CLL
Total p73 mRNA expression was measured quantita-
tively by real-time RT-PCR using p73 primers spanning
exon 5 and 6, a region without any known splice sites
[6-8]. The expression of total p73 mRNA was signifi-
cantly higher in the 51 B-CLL patient samples compared
to a population of normal CD19+-B-lymphocytes ob-
tained from eight individuals (Figure 1, P - 0.01).
Among particular B-CLL risk groups, the expression
of total p73 mRNA was higher in the intermediate risk
(P = 0.013) and in the high risk B-CLL group (P =
0.007) than in normal B-lymphocytes, but there was no
difference between the low risk and the high risk/im-
mune group (data not shown in Figure 1). The cell lines
JVM-2 and K562 expressed high levels of p73 mRNA
whereas expression was very low or undetectable in













Figure I. Absolute total p73 and p-actin RNA transcript numbers as
assessed by real-time quantitative RT-PCR in a population of normal
CD19.+-B-lymphocytes and B-CLL samples. Results are depicted as
the 95% confidential interval (CI) of the ratio of log values of the
mean. Total p73 mRNA expression in B-CLL (all risk groups) is
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Figure 2. Expression of p73 C-terminal mRNA splice variants and p73 protein analysis of a population of normal CD19+-B-lymphocytes and
representative samples of patients with B-CLL from two different risk groups. Each lane represents p73 mRNA and protein data from a particular
sample. By increasing the exposure time, all p73 C-terminal mRNA splice variants outlined in Table 1 can be detected. 'Additional proteins other
than p73a.
Table I. Expression of the p73 gene in a population of normal CD19+-B-lymphocytes. patients with B-CLL. and cell lines. See 'Materials and

























































































































































"' Number of samples in which a particular C-terminal mRNA splice variant or protein was detected: cell lines- X - detected; O - not detected;
b
 In addition to p73a as shown in Figure 2. p73 mRNA C-terminal splice variants y (P = 0.041). G (P < 0.001). and the r) (P = 0.033) prevailed in
normal B-lymphocytes. Prevalent detection of the p73a protein in B-CLL samples compared to normal B-lymphocytes (P = 0.008) and positive
correlation with higher risk B-CLL stages (P = 0.046).
The expression ofp73 C-terminal mRNA splice variants
is biased
The investigation of p73 C-terminal mRNA splice var-
iants by RT-PCR showed that many different variants
were expressed in normal and malignant samples. The
majority of both B-CLL and normal B-lymphocyte
samples expressed the larger p73 C-terminal splice var-
iants oc, p, and e (Table 1 and Figure 2). The C, variant was
detected in a subset of B-CLL (10 of 51) and normal
B-lymphocytes (1 of 8) only. The y variant was more
frequently expressed in normal B-lymphocytes than in
B-CLL (P = 0.041) as were the shorter mRNA splice
variants 6 (P < 0.001) and r\ {P = 0.033). Table 1
summarises the expression of p73 mRNA C-terminal
splice variants in the lymphoid and the myeloid cell lines
included in our study. In contrast to published data [14],
RPM1-8402 was found to express p73a mRNA, and
Kasumi-1 expressed the p73 mRNA variants a and [3
(Table 1).
p73a protein expression is positively correlated with
higher risk B-CLL stages
p73 protein expression was investigated by Western blot
using a rabbit polyclonal antibody [5]. We detected the
984
p73a protein in 33 of 51 B-CLL patient samples, but
only in one of eight samples of normal B-lymphocytes
(P = 0.008). Ten of twelve samples from high risk, but
only two of six samples from low risk B-CLL patients
expressed detectable levels of the p73a protein (Table 1
and Figure 2). Sixteen of 51 B-CLL and 7 of 8 B-lym-
phocyte samples expressed total p73 mRNA but no
p73a protein, and in 2 of 51 B-CLL samples, neither
was found. Detection of the p73oc protein was positively
correlated with higher risk B-CLL stages (P = 0.046).
Western blot analysis revealed a complex pattern of
proteins (Table 1, Figure 2). The p73oc protein was
identified by its comigration with the in vitro translated
p73a product (data not shown). None of the additional
smaller bands comigrated with in vitro translated p73(3
which is also detected by the polyclonal antibody used
(data not shown). In normal B-lymphocyte samples, a
band of approx. 56 kD was present and was the only
signal in 7 of 8 B-lymphocyte samples (Figure 2). This
band was not exclusive to normal B-lymphocytes, but
was also detected in B-CLL samples. In a subset of
B-CLL samples of different risk groups, additional
bands were detected in the absence of p73a (data not
shown). The polyclonal antibody did not detect any
proteins in the K.asumi-1 and the Jurkat cell lines which
both express p73 mRNA at very low or undetectable
levels as measured by real-time RT-PCR (data not
shown).
Discussion
The results of this survey on the expression of p73 in
B-CLL and normal CD19+- B-lymphocytes have re-
vealed several novel features. In B-CLL, total p73
mRNA expression is significantly higher than in a nor-
mal B-lymphocyte population. A detailed analysis of the
p73 C-terminal mRNA splice variants yields a biased
expression pattern since the shorter p73 variants y, 9,
and r| prevail in the normal B-lymphocyte population
studied. p73a protein expression is significantly more
frequent in B-CLL samples than in normal B-lympho-
cytes. Importantly, the expression of the p73a protein is
positively correlated with higher risk B-CLL stages.
It was suggested that p73 acts as a tumour suppressor
gene in ALL and Burkitt's lymphoma and loss of its
function would contribute to the development and the
progression of such lymphoid neoplasms [8, 13, 14]. In
contrast to these reports and in agreement with prior
investigations in hepatocellular carcinoma [18] and
bladder cancer [19], we have shown that in B-CLL, p73
expression is positively correlated with disease progres-
sion. This supports a possible oncogenic role of p73 in
B-CLL.
The differences in the expression pattern of p73 be-
tween B-CLL, B-NHL and ALL may reflect differences
in the biology of these groups of lymphoid malignancies.
A link of the expression of the p73 gene to lymphoid
differentiation is possible. The p73 gene is overexpressed
in progressive B-CLL which is characterized by an
accumulation of non-proliferating, senescent cells with
disrupted apoptosis [2, 28]. In mature ALL, lack of p73
expression was suggested to contribute to the high pro-
liferation rate [8]. p73 overexpression was initially
shown to induce cell cycle and growth arrest as well as
apoptosis in a series of cell lines [5, 6, 10]. Interestingly,
recent reports on other cell lines confirmed the induc-
tion of cell cycle and growth arrest by overexpression of
p73, but without apoptosis and in the presence of repli-
cative senescence [9, 29]. Thus, the effect of p73 expres-
sion may be tissue-specific [5, 6, 30]. This may partially
explain the apparent paradox that this gene is overex-
pressed in a variety of malignancies with disrupted
apoptosis including B-CLL whilst inducing apoptosis in
other cell types.
Earlier reports on malignancies other than B-CLL
suggested that instability in the splicing of p73 exons
preferentially occurs in cancer cells [11, 26]. We found
that various p73 mRNA splice variants are expressed in
both B-CLL and normal B-lymphocyte samples, but in
different patterns. Shorter p73 mRNA splice variants
prevailed in normal B-lymphocytes, although none of
the p73 variants was restricted to either normal or
malignant samples in our series. The shorter p73 splice
variants such as y, e, 5 are less effective in activating
p53-responsive genes than p73a [6]. The recently identi-
fied p73 variants 0, r\, and r)l lack the p73 C-terminal
transactivation domain and the region of homology
with the p53 oligomerization domain [8]. Some of the
p73 variants exhibit p53-like functions or inhibit p53
while others may carry out yet unknown p73-specific
functions [31]. In addition to the C-terminal splice var-
iants, 2 different N-terminal p73 mRNA variants have
recently been described [5, 16]. In mice, one of them, the
ANp73 variant, was shown to act as a dominant neg-
ative inhibitor of p73a and p53 [16, 32]. These data
suggest that the balance of expressed p73 variants may
determine the function of the protein. E2F-1 is a tran-
scriptional factor which can act as an oncogene or a
tumour-suppressor gene [33]. The recently reported
interactions of p73 with E2F1 [33] will help to clarify
the role of p73 as a pro- or antiapoptotic actor in
malignant diseases.
Earlier investigations on p73 mRNA expression in
clinical samples have shown that p73 is overexpressed in
a variety of malignancies with respect to their normal
cellular counterparts [11, 25, 26]. Our data suggest that
this is true for B-CLL with respect to normal CD19+-
B-lymphocytes. Expression of the p73 gene may differ
between various other subpopulations of B cells including
CD5+-B-cells, which have been purported to represent
normal counterparts of B-CLL cells [34, 35]. A compre-
hensive survey of p73 expression in all normal B-cell
subtypes as well as other B-cell malignancies expressing
the CD5 marker such as mantle cell lymphomas would
be of some interest and warrant further investigation.
Overexpression of the p73 gene in B-CLL is unlikely
to be linked to treatment since only a minority of our
985
patients (8 of 51) were under treatment at the time of
sample collection and the regimens did not contain
drugs known to up-regulate p73 [11].
In agreement with prior reports [5, 12, 24, 25], p73
protein western analysis revealed the presence of several
additional protein bands in all types of samples included
in our series (Table 1, Figure 2). To investigate the nature
of these additional proteins, we treated three different
cell lines (JVM-2, MCF-7, and Calu-1) with N-acetyl-
leucinyl-leucinyl-norleucinal (LLnL, MG-101, Sigma;
Buchs, Switzerland) which inhibits ubiquitin-dependent
protein degradation by the proteasome [12]. Evidence
for protein degradation was only found in the JVM-2
cell line. The treatment with LLnL led to a transient
band shift in JVM-2 as previously shown for other cell
lines [12] (data not shown). The additional protein bands
seen are currently under investigation, and may repre-
sent either p73 variants or posttranscriptional modifica-
tions of p73. New antibodies are needed to identify all
known p73 variants.
In summary, we conclude that the accumulation of
p73, the expression pattern of particular p73 variants
and its link to progression may play a distinct role in the
molecular pathology B-CLL.
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